Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.98 USD
+0.03 (3.53%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.99 +0.01 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LCTX 0.98 +0.03(3.53%)
Will LCTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for LCTX
LCTX: Analyst Jason Kolbert from D. Boral Capital Maintains Buy Rating | LCTX Stock News
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business ...
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and ...
Lineage Cell Therapeutics doses first patient in DOSED study
BlackRock, Inc. Significantly Reduces Holdings in Lineage Cell Therapeutics Inc